PI
Proteonomix, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Byle Steve Mark, was filed 30 Nov 2009.
Proteonomix, Inc.: what insiders have been doing
Every trade that managers of Proteonomix, Inc. disclose to SEC (Form 4) is tracked on this page. The past year has been quiet: not a single insider filing for Proteonomix, Inc. The previous disclosure was published on 28 September 2011.
Looking back to 2009, when coverage begins, insiders filed 6 purchases and no sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
12
Thresholds
n/a
Buy Volume
€284,091
6 ops. · all time
Sell Volume
n/a
n/a
Financial data
· cache
US$0.00
Analyst consensus
Income statement
EBITDA-US$3.4M
Valuation
Beta-46.95
Profitability & ownership
ROA-51.0%
% institutions0.0%
Last declaration on 28 September 2011
Declarations12 total
- 25,000 shares@ US$17,500.00Common StockSEC:0001041183-11-000003:0
- 200,000 shares@ US$0.50COMMON STOCKSEC:0001091818-11-000553:0
- 25,000 shares@ US$5,000.00Common StockSEC:0001041183-11-000002:0
- 178,572 shares@ US$0.56Common StockSEC:0001091818-10-000579:0
- 375,000 shares@ US$0.56Common StockSEC:0001091818-10-000578:0
- 250,000 shares@ US$0.45Common StockSEC:0001091818-10-000566:0
- 4,000 shares@ US$0.85Common StockSEC:0001091818-09-000345:1Canonical exit: 28 Jan 2010 (T+90)
- 50,000 shares@ US$1.50COMMON STOCKSEC:0001091818-09-000338:0Canonical exit: 14 Feb 2010 (T+90)
- 100,000 sharesCommon StockSEC:0001091818-09-000335:0Canonical exit: 14 Feb 2010 (T+90)
- 499 shares@ US$0.81Common StockSEC:0001091818-09-000296:0Canonical exit: 28 Jan 2010 (T+90)
- 4,000 shares@ US$85.00Common StockSEC:0001091818-09-000296:1Canonical exit: 28 Jan 2010 (T+90)
- 1,001 shares@ US$1.00Common StockSEC:0001091818-09-000296:2Canonical exit: 28 Jan 2010 (T+90)
12 of 12 declarations
About Proteonomix, Inc.
Proteonomix, Inc. is a NASDAQ-listed company focused on developing biopharmaceutical solutions. It specializes in the research and commercialization of products based on proteomics.
